Astellas Builds Vaccine Portfolio With Affinivax Pneumococcal Candidate
Executive Summary
Despite one recent setback, Astellas is continuing to expand its vaccines business through a new global deal for Affinivax's lead MAPS pneumococcal product, in a move that builds on earlier research links between the companies.
You may also be interested in...
Affinivax's 24-Valent Pneumococcal Vaccine Targets Growing And Changing Market
A potential next-generation, 24-valent, pneumococcal vaccine in development by Affinivax and Astellas has shown strong immunogenicity in a Phase II study and is preparing to enter pivotal Phase III trials; if successful, it will target a growing market currently dominated by big pharma players.
With Prevnar Challenger Fully Funded, Affinivax Raises $120m For Other Novel Vaccines
Astellas is funding the company’s Phase II vaccine against 24 pneumococcal serotypes. Affinivax will use its series B venture cash to advance its MAPS vaccines for bacterial and viral infections and cancer.
Affinivax’s MAPS Vaccine Technology Reaches Clinic In Under Five Years
Funded entirely by grants and partnerships to date, Affinivax’s pneumococcal vaccine candidate has begun a Phase I/II study less than five year’s after the biotech’s founding. Firm thinks its technology may eventually apply to immuno-oncology as well.